Abstract:perknesis. The localized nature of the itch at the same level of previous pain suggested a neuropathic cause and was diagnosed as notalgia paresthetica. Magnetic resonance imaging (MRI) of his thoracic spine did not reveal any nerve impingement. He had tried various therapies including antihistamines and topical capsaicin prior to visiting our clinic but without success. He had also previously taken gabapentin 300 mg daily for 2 weeks but this only caused an additional burning sensation on the affected area. The patient was started on amitriptyline 10 mg once a night. At 2 months, the severity of itch decreased from 7 to 5 on a scale of 10. The frequency of itch also decreased from three to two daily. When the patient tried increasing the dose of amitriptyline to 20 mg o.n., he started feeling drowsy. He was therefore continued on a dose of 10 mg o.n. and at 3 months, his itch severity decreased to 4. He felt that the level of itch had become controlled and he was able to function normally in his daily life. After 9 months of treatment, the patient stopped taking amitriptyline himself for a month and control of itch remained sustained. Notalgia paresthetica is a prototype of neuropathic itch, arising from a disorder along the sensory neural pathways and resulting in an itch sensation independent of physical stimuli. Specifically, the affected nerves in notalgia paresthetica are the dorsal rami of the thoracic spinal nerves, most commonly T2–T6. However, correlation between radiological findings of vertebral pathology and dermatomal localization of notalgia paresthetica is often low. Our patient did not have MRI evidence of thoracic cord compression or impingement of exiting thoracic nerve roots. The posterior rami of the T2–T6 thoracic nerves run a right-angled course through the multifidus spinae muscles, making them more prone injury by muscular impingement or trauma despite a normal radiological study. Based on this theory, the reason for our patient initially feeling pain and subsequently feeling itch over his back may be related to a greater and then lesser degree of compression of the peripheral nerve over time. Oral medications that target neurons such as gabapentin and oxcarbazepine have been successful only in some patients. In our patient, in whom gabapentin treatment failed, amitriptyline proved to be efficacious. Amitriptyline is a tricyclic antidepressant traditionally used in psychiatric mood disorders and found also to be useful in neuropathic itch. Its mechanism of action in nostalgia paresthetica may possibly be related to inhibition of voltage-dependent ion channels in impinged peripheral nerves and nicotinic acetylcholine receptors in unmyelinated nociceptive axons. The usual dose of amitriptyline for treatment of depression is between 40 and 150 mg daily and the main side-effects are sedation and anticholinergic effects. Our patient responded well to just 10 mg of amitriptyline o.n. without any side-effects. In summary, we first describe a patient with nostalgia paresthetica who failed conventional pharmacotherapeutic treatment and responded well to low-dose amitriptyline. Amitriptyline may possibly be a useful alternative for treatment of the disease.

tiRNA‐Gly‐GCC‐001 in major depressive disorder: Promising diagnostic and therapeutic biomarker

Blood Mir-144-3p: a Novel Diagnostic and Therapeutic Tool for Depression

Microarray Analysis of the Major Depressive Disorder Mrna Profile Data.

Bilaterally localized terminal hair growth on the trunk

The role of circulating blood microRNA-374 and microRNA-10 levels in the pathogenesis and therapeutic mechanisms of major depressive disorder

MicroRNA-451a is a candidate biomarker and therapeutic target for major depressive disorder

Peripheral Blood Mononuclear Cell Biomarkers for Major Depressive Disorder: A Transcriptomic Approach

Abnormal Expression Profile of Plasma-Derived Exosomal Micrornas in Patients with Treatment-Resistant Depression

Exosomal let-7e, miR-21-5p, miR-145, miR-146a and miR-155 in Predicting Antidepressants Response in Patients with Major Depressive Disorder

The Link Between Long Noncoding RNAs and Depression.

Differentially expressed genes related to major depressive disorder and antidepressant response: genome-wide gene expression analysis

Integrated Single‐Cell RNA‐seq and ATAC‐seq Reveals Heterogeneous Differentiation of CD4+ Naive T Cell Subsets is Associated with Response to Antidepressant Treatment in Major Depressive Disorder

A brain-enriched circRNA blood biomarker can predict response to SSRI antidepressants

Advances in biosensors for major depressive disorder diagnostic biomarkers

Screening and identification of key biomarkers of depression using bioinformatics

Identification of Specific Plasma miRNAs as Potential Biomarkers for Major Depressive Disorder

MicroRNAs as diagnostic biomarkers and predictors of antidepressant response in major depressive disorder: a systematic review

Diagnostic Biomarker Hsa_circ_0126218 and Functioning Prediction in Peripheral Blood Monocular Cells of Female Patients With Major Depressive Disorder

LRFN5 and OLFM4 as novel potential biomarkers for major depressive disorder: a pilot study

Clinical and preclinical evaluation of miR-144-5p as a key target for major depressive disorder

TCF4 and RBFOX1 as peripheral biomarkers for the differential diagnosis and treatment of major depressive disorder